Medicine and Dentistry
Overall Survival
100%
Disease
95%
Stomach Cancer
63%
Pancreas Cancer
58%
Neoplasm
57%
Krukenberg Tumor
55%
Pancreas Islet Cell Tumor
55%
Rectum Cancer
55%
Lymph Node
38%
Retrospective Study
37%
Disease Free Survival
37%
Surgery
37%
BRCA Mutation
33%
Placebo
31%
Postoperative Complication
31%
Colon Cancer
29%
Cross Sectional Study
27%
Osteolysis
27%
COVID-19
27%
Diabetes Mellitus
27%
Pembrolizumab
27%
Dysglycemia
27%
Chemoradiotherapy
27%
Phase II Trials
27%
Stomach Adenocarcinoma
27%
Zoledronic Acid
27%
Clinical Trial
27%
Paclitaxel
27%
Breast Cancer
27%
Thyroid Cancer
27%
Doxorubicin
27%
Biological Marker
27%
Tomography
27%
Postmenopause
27%
Gallium 68
27%
Carboplatin
27%
Letrozole
27%
Tamoxifen
27%
Vemurafenib
27%
Telemedicine
27%
Fluorodeoxyglucose F 18
27%
Esophageal Cancer
27%
Radiation Therapy
27%
Intraperitoneal Chemotherapy
27%
Lymphocytopenia
27%
Pancreas Fistula
27%
Peritoneum Metastasis
27%
Pancreaticoduodenectomy
27%
Pancreas Adenocarcinoma
27%
Treatment Response
27%
Keyphrases
Overall Survival
72%
Neoadjuvant
59%
Chemotherapy
57%
Oncology Patients
55%
FOLFIRINOX
55%
Resectable Pancreatic Cancer
55%
Colorectal Cancer
40%
Retrospective Analysis
40%
BRCA mutation
37%
Improved Outcomes
34%
Protective Effect
31%
Placebo
31%
Disease-free Survival
31%
Confidence Interval
31%
Cancer Patients
31%
Postoperative Complications
31%
Neoadjuvant Therapy
30%
Pancreatic Neuroendocrine Tumors (pNETs)
30%
5-year Survival
30%
Borderline Resectable Pancreatic Cancer
29%
Tumor
28%
Oxaliplatin
28%
Prospective Randomized Trial
27%
Paclitaxel
27%
Cannabis
27%
Bone Loss
27%
Nonfunctional Pancreatic Neuroendocrine Tumor
27%
Type 1 Diabetes Mellitus (T1DM)
27%
68Ga-FAPI
27%
Dysglycemia
27%
Postmenopausal Women
27%
Activating mutation
27%
Zoledronic Acid
27%
Randomized Double-blind
27%
Long-term Response
27%
Thyroid Cancer
27%
Oxaliplatin-induced Neuropathy
27%
Metastatic Gastric Cancer
27%
Lymph Node Ratio
27%
Advanced Ovarian Cancer
27%
Advanced Gastric Cancer
27%
Locally Advanced Rectal Cancer
27%
Clinical Outcomes
27%
Carboplatin
27%
Microscopic Disease
27%
Clinical Experience
27%
Randomized Phase II Trial
27%
Multi-key Homomorphic Encryption
27%
Chemoradiotherapy
27%
Progression-free Survival
27%
Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
66%
Ovary Carcinoma
55%
Chemotherapy
48%
Neoplasm
48%
Disease
48%
Postoperative Complication
31%
Retrospective Study
31%
Pancreas Cancer
31%
Diabetes Mellitus
29%
Colon Cancer
29%
Oxaliplatin
28%
Paclitaxel
27%
Stomach Cancer
27%
Chemoradiation Therapy
27%
Pancreas Islet Cell Tumor
27%
Oxaliplatin-Induced Peripheral Neuropathy
27%
Rectum Cancer
27%
Zoledronic Acid
27%
Irritable Colon
27%
Thyroid Cancer
27%
Phase II Trials
27%
Tamoxifen
27%
Doxorubicin
27%
Posttraumatic Stress Disorder
27%
Placebo
27%
Dysglycemia
27%
Vemurafenib
27%
Carboplatin
27%
Letrozole
27%
Pembrolizumab
27%
Breast Cancer
27%
Cannabis
27%
Pancreas Fistula
27%
Peritoneum Metastasis
27%
Pancreas Adenocarcinoma
27%
Intraperitoneal Chemotherapy
27%
Impaired Glucose Tolerance
18%
Disease Free Survival
18%
Prevalence
15%
Progression Free Survival
12%
Chemotherapy-Induced Peripheral Neuropathy
11%
Neuropathy
11%
Carcinoma
11%
Recurrent Disease
9%
Hormone Receptor
9%
Malignant Neoplasm
9%
Survival Rate
9%
Melanoma
7%
Adenocarcinoma
6%
Symptom
6%